Abstract
Marine omega-3 rich oils are used by more than a third of American adults for a wide range of purported benefits including prevention of cardiovascular disease. These oils are highly prone to oxidation to lipid peroxides and other secondary oxidation products. Oxidized oils may have altered biological activity making them ineffective or harmful, though there is also evidence that some beneficial effects of marine oils could be mediated through lipid peroxides. To date, human clinical trials have not reported the oxidative status of the trial oil. This makes it impossible to understand the importance of oxidation to efficacy or harm. However, animal studies show that oxidized lipid products can cause harm. Oxidation of trial oils may be responsible for the conflicting omega-3 trial literature, including the prevention of cardiovascular disease. The oxidative state of an oil can be simply determined by the peroxide value and anisidine value assays. We recommend that all clinical trials investigating omega-3 harms or benefits report the results of these assays; this will enable better understanding of the benefits and harms of omega-3 and the clinical importance of oxidized supplements.
1. Introduction
Marine omega-3 rich oils (marine oils) are the most popular supplements in the United States; after a rapid rise in popularity, they are now used by more than a third of American adults [
1,P. M. Barnes, E. Powell-Griner, K. McFann, and R. L. Nahin, “Complementary and alternative medicine use among adults: United States, 2002,” Advance Data, no. 343, pp. 1–19, 2004.
View at: Google Scholar
P. C. Calder, “n-3 fatty acids and cardiovascular disease: evidence explained and mechanisms explored,” Clinical Science, vol. 107, no. 1, pp. 1–11, 2004.
View at: Publisher Site | Google Scholar
P. C. Calder, “Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?” British Journal of Clinical Pharmacology, vol. 75, pp. 645–662, 2013.
View at: Google Scholar
J. E. Karr, J. E. Alexander, and R. G. Winningham, “Omega-3 polyunsaturated fatty acids and cognition throughout the lifespan: a review,” Nutritional Neuroscience, vol. 14, no. 5, pp. 216–225, 2011.
View at: Publisher Site | Google Scholar
N. S. Kalupahana, K. J. Claycombe, and N. Moustaid-Moussa, “(n-3) fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights,” Advances in Nutrition, vol. 2, pp. 304–316, 2011.
View at: Publisher Site | Google Scholar
N. Matsuo, “Studies on the toxicity of fish oil,” The Journal of Biochemistry, vol. 41, pp. 481–487, 1954.
View at: Google Scholar
2. How Stable Are Marine Omega-3 Supplements?
n-3 LC-PUFAs are chemically unstable, so that marine oils rapidly oxidize during storage to a complex chemical soup of lipid peroxides, secondary oxidation products, and diminishing concentrations of unoxidized fatty acids. As a result, the composition of a fish oil supplement cannot be simply inferred from the labelled EPA and DHA concentrations.
n-3 LC-PUFAs are highly prone to oxidation due to their large number of double bonds and their position within the fatty acid chain [
8,I. F. F. Benzie, “Lipid peroxidation: a review of causes, consequences, measurement and dietary influences,” International Journal of Food Sciences and Nutrition, vol. 47, no. 3, pp. 233–261, 1996.
View at: Google Scholar
F. Shahidi and Y. Zhong, “Lipid oxidation and improving the oxidative stability,” Chemical Society Reviews, vol. 39, no. 11, pp. 4067–4079, 2010.
View at: Publisher Site | Google Scholar
F. Shahidi and Y. Zhong, “Lipid oxidation and improving the oxidative stability,” Chemical Society Reviews, vol. 39, no. 11, pp. 4067–4079, 2010.
View at: Publisher Site | Google Scholar
A. Barden, E. Mas, P. Henry et al., “The effects of oxidation products of arachidonic acid and n3 fatty acids on vascular and platelet function,” Free Radical Research, vol. 45, no. 4, pp. 469–476, 2011.
View at: Publisher Site | Google Scholar
Lipid peroxides are unstable and further degrade to form secondary oxidation products including aldehydes such as 4-hydroxyhexenal (HHE) and malondialdehyde (MDA) [
11]. As the oil oxidizes over time, there is an initial exponential increase in the concentration of lipid peroxides. These later degrade and the concentration of potentially harmful secondary oxidation products increases as the lipid peroxides decrease.The rate of lipid peroxidation is influenced by light, heat, and oxygen concentration even at normal room conditions. Moreover, even oil stored in the dark at 4°C may oxidize unacceptably within a month of storage [
12]. Added antioxidants reduce but do not prevent oxidation [P. C. Zuta, B. K. Simpson, X. Zhao, and L. Leclerc, “The effect of α-tocopherol on the oxidation of mackerel oil,” Food Chemistry, vol. 100, no. 2, pp. 800–807, 2007.
View at: Publisher Site | Google Scholar
F. Shahidi and Y. Zhong, “Lipid oxidation and improving the oxidative stability,” Chemical Society Reviews, vol. 39, no. 11, pp. 4067–4079, 2010.
View at: Publisher Site | Google Scholar
Oil in an omega-3 supplement may differ substantially from the oil in fresh fish depending on its age, heat and light exposure. As a result, these supplements should be viewed as a complex mix of EPA, DHA, other fatty acids, additives, and an unspecified concentration of potentially toxic lipid peroxides and secondary oxidation products.
3. Can Oxidation Be Easily Quantified and Reported?
Measurement of specific lipid peroxide species and secondary oxidation products requires gas-chromatography mass-spectrometry [
14–A. E. Barden, K. D. Croft, T. Durand, A. Guy, M. J. Mueller, and T. A. Mori, “Flaxseed oil supplementation increases plasma F1-phytoprostanes in healthy men,” Journal of Nutrition, vol. 139, no. 10, pp. 1890–1895, 2009.
View at: Publisher Site | Google Scholar
I. F. F. Benzie, “Lipid peroxidation: a review of causes, consequences, measurement and dietary influences,” International Journal of Food Sciences and Nutrition, vol. 47, no. 3, pp. 233–261, 1996.
View at: Google Scholar
European Pharmacopoeia Commission, “European Pharmacopoeia 5.0,” Council of Europe, 2005, http://lib.njutcm.edu.cn/yaodian/ep/EP5.0/index.html.
View at: Google Scholar
A number of organisations have endorsed maximum recommended levels of oxidation in supplements [
19–USA Council for Responsible Nutrition, “Voluntary Monograph: Omega-3 DHA, Omega-3 EPA, Omega-3 DHA & EPA,” 2006, http://www.crnusa.org/pdfs/O3FINALMONOGRAPHdoc.pdf.
View at: Google Scholar
Global Organization for EPA and DHA Omega-3, “GOED Voluntary Monograph (v.4),” 2012, http://www.goedomega3.com/images/stories/files/goedmonograph.pdf.
View at: Google Scholar
4. Are Over-the-Counter Marine Omega-3 Supplements Significantly Oxidized?
The oxidative states of retail oils are not routinely labelled and it is surprising that there has not been more formal evaluation of the oxidative stability of marketed omega-3 supplements. When over-the-counter supplements have been investigated, the frequency of excess oxidation [
19–USA Council for Responsible Nutrition, “Voluntary Monograph: Omega-3 DHA, Omega-3 EPA, Omega-3 DHA & EPA,” 2006, http://www.crnusa.org/pdfs/O3FINALMONOGRAPHdoc.pdf.
View at: Google Scholar
B. L. Halvorsen and R. Blomhoff, “Determination of lipid oxidation products in vegetable oils and marine omega-3 supplements,” Food and Nutrition Research, vol. 55, no. 1, 2011.
View at: Publisher Site | Google Scholar
C. M. Fantoni, A. P. Cuccio, and D. Barrera-Arellano, “Brazilian encapsulated fish oils: oxidative stability and fatty acid composition,” Journal of the American Oil Chemists' Society, vol. 73, no. 2, pp. 251–253, 1996.
View at: Google Scholar
5. Are Oxidized Omega-3 Oils Efficacious?
To our knowledge, no clinical trial investigating the efficacy of omega-3 in humans has reported the oxidative state of the trial oil or compared oxidized and nonoxidized oils. The relative efficacy of highly oxidized and nonoxidized oil cannot be inferred. However, it is likely that there is a difference.
The mechanisms of action of omega-3 are not fully understood, but there are multiple interacting mechanisms including acting as a ligand for intracellular and extracellular receptors, competition for metabolism by enzymes, structural roles in cell membrane, and stearic interference with ion channels. For illustration, triglyceride lowering is mediated by interaction with sterol receptor binding protein 1-c (SREBP1-c) and the peroxisome proliferator activated receptor alpha (PPAR-α) [
28]. Anti-inflammatory, hypotensive, and antiplatelet effects may be mediated by competition with arachidonic acid for synthesis of eicosanoids by the enzyme cyclooxygenase [P. C. Calder, “n-3 fatty acids and cardiovascular disease: evidence explained and mechanisms explored,” Clinical Science, vol. 107, no. 1, pp. 1–11, 2004.
View at: Publisher Site | Google Scholar
R. De Caterina, R. Madonna, R. Zucchi, and M. T. La Rovere, “Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside,” American Heart Journal, vol. 146, no. 3, pp. 420–430, 2003.
View at: Publisher Site | Google Scholar
N. S. Kalupahana, K. J. Claycombe, and N. Moustaid-Moussa, “(n-3) fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights,” Advances in Nutrition, vol. 2, pp. 304–316, 2011.
View at: Publisher Site | Google Scholar
D. Y. Oh, S. Talukdar, E. J. Bae et al., “GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects,” Cell, vol. 142, no. 5, pp. 687–698, 2010.
View at: Publisher Site | Google Scholar
D. Richard, K. Kefi, U. Barbe, P. Bausero, and F. Visioli, “Polyunsaturated fatty acids as antioxidants,” Pharmacological Research, vol. 57, no. 6, pp. 451–455, 2008.
View at: Publisher Site | Google Scholar
S. E. Feller, K. Gawrisch, and A. D. MacKerell Jr., “Polyunsaturated fatty acids in lipid bilayers: intrinsic and environmental contributions to their unique physical properties,” Journal of the American Chemical Society, vol. 124, no. 2, pp. 318–326, 2002.
View at: Publisher Site | Google Scholar
As lipid peroxides have different shape, polarity, and reactivity to their parent fatty acid, it is likely that they will be ineffective through some if not all of these mechanisms. Because these mechanisms are diverse, the effect of oxidized supplements may be divergent, some beneficial effects may be lost but not others; lipid peroxides may even have their own unique functions.
Surprisingly, there are no specific clinical trials investigating the effects of oxidation on the efficacy of marine n-3. However, in a clinical trial of fish oil supplementation with and without the anti-oxidant vitamin E, triglycerides decreased significantly more in the vitamin E group [
33]. Increased efficacy with vitamin E is most likely due to prevention of oxidation of the oil either prior to consumption or in vivo. Interestingly, in a study of liver tissue in culture, oxidized EPA inhibited the inflammatory NF-κB pathway [A. Mishra, A. Chaudhary, and S. Sethi, “Oxidized omega-3 fatty acids inhibit NF-κB activation via a PPARα-dependent pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 9, pp. 1621–1627, 2004.
View at: Publisher Site | Google Scholar
J. D. Brooks, E. S. Musiek, T. R. Koestner et al., “The fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation,” Journal of Neurochemistry, vol. 119, no. 3, pp. 604–616, 2011.
View at: Publisher Site | Google Scholar
A. Barden, E. Mas, P. Henry et al., “The effects of oxidation products of arachidonic acid and n3 fatty acids on vascular and platelet function,” Free Radical Research, vol. 45, no. 4, pp. 469–476, 2011.
View at: Publisher Site | Google Scholar
6. Are Oxidized Omega-3 Supplements Harmful?
There are insufficient interventional human studies that examine potential biological functions of oxidized marine n-3; however, there is evidence that lipid peroxidation is involved in human disease. In addition, animal studies show that oxidized lipids may cause organ damage, inflammation, carcinogenesis, and advanced atherosclerosis. These deleterious effects cannot be ignored, particularly when marine n-3 is taken during vulnerable stages of life such as pregnancy, early childhood, and old age and for long periods of time.
Lipid peroxides are absorbed through the gut and incorporated into chylomicrons [
36], LDL [M. Ahotupa, J. P. Suomela, T. Vuorimaa, and T. Vasankari, “Lipoprotein-specific transport of circulating lipid peroxides,” Annals of Medicine, vol. 42, no. 7, pp. 521–529, 2010.
View at: Publisher Site | Google Scholar
J. P. Suomela, M. Ahotupa, O. Sjövall, J. P. Kurvinen, and H. Kallio, “Diet and lipoprotein oxidation: analysis of oxidized triacylglycerols in pig lipoproteins,” Lipids, vol. 39, no. 7, pp. 639–647, 2004.
View at: Publisher Site | Google Scholar
H. Esterbauer, “Cytotoxicity and genotoxicity of lipid-oxidation products,” American Journal of Clinical Nutrition, vol. 57, no. 5, pp. 779S–785S, 1993.
View at: Google Scholar
J. T. Salonen, S. Ylä-Herttuala, R. Yamamoto et al., “Autoantibody against oxidised LDL and progression of carotid atherosclerosis,” The Lancet, vol. 339, no. 8798, pp. 883–887, 1992.
View at: Google Scholar
K. Kanazawa and H. Ashida, “Dietary hydroperoxides of linoleic acid decompose to aldehydes in stomach before being absorbed into the body,” Biochimica et Biophysica Acta, vol. 1393, no. 2-3, pp. 349–361, 1998.
View at: Publisher Site | Google Scholar
Lipid peroxides hasten oxidation of other fatty acids to create further lipid peroxides in an expansive chain reaction. We speculate that ingested omega-3 peroxides could lead to lipid membrane peroxidation, cell damage, and oxidative stress, which are known to be mechanisms of disease. Endogenous membrane lipid peroxidation results in altered membrane fluidity, transport, and cell signalling [
8] which also may be an important disease mechanism. For example, acute severe lipid and protein peroxidation has been shown to be the cause of death when, despite appropriate treatment, people die from organophosphate poisoning [J. Vidyasagar, N. Karunakar, M. S. Reddy, K. Rajnaranyana, T. Surender, and D. R. Krishna, “Oxidative stress and antioxidant status in acute organophosphorous insecticide poisoning,” Indian Journal of Pharmacology, vol. 36, no. 2, pp. 76–79, 2004.
View at: Google Scholar
H. Bartsch and J. Nair, “Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair,” Langenbeck's Archives of Surgery, vol. 391, no. 5, pp. 499–510, 2006.
View at: Publisher Site | Google Scholar
L. M. Sayre, D. A. Zelasko, P. L. R. Harris, G. Perry, R. G. Salomon, and M. A. Smith, “4-hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease,” Journal of Neurochemistry, vol. 68, no. 5, pp. 2092–2097, 1997.
View at: Google Scholar
R. van den Berg, G. R. M. M. Haenen, H. van den Berg, and A. Bast, “Transcription factor NF-κB as a potential biomarker for oxidative stress,” British Journal of Nutrition, vol. 86, no. 1, pp. S121–S127, 2001.
View at: Google Scholar
P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143, 2002.
View at: Publisher Site | Google Scholar
A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, “Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS),” Circulation, vol. 102, no. 1, pp. 42–47, 2000.
View at: Google Scholar
Animal studies provide clear evidence that oxidized lipids are harmful, though typically using higher doses of oil than humans consume or administering oxidation products in nonphysiological ways [
11]. Chronic feeding of oxidized PUFAs to rats led to growth retardation, intestinal irritation, liver and kidney enlargement, haemolytic anaemia, decreased vitamin E, increased lipid peroxides and inflammatory changes in the liver, cardiomyopathy, and potentially malignant colon cell proliferation [H. Esterbauer, “Cytotoxicity and genotoxicity of lipid-oxidation products,” American Journal of Clinical Nutrition, vol. 57, no. 5, pp. 779S–785S, 1993.
View at: Google Scholar
H. Esterbauer, “Cytotoxicity and genotoxicity of lipid-oxidation products,” American Journal of Clinical Nutrition, vol. 57, no. 5, pp. 779S–785S, 1993.
View at: Google Scholar
H. Bartsch and J. Nair, “Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair,” Langenbeck's Archives of Surgery, vol. 391, no. 5, pp. 499–510, 2006.
View at: Publisher Site | Google Scholar
There is increasing evidence that in vivo oxidation of LDL has a role in atherogenesis [
47]. Unmodified LDL cannot induce foam cell formation; however, after oxidative modification it can be recognised by the scavenger receptor of macrophages and is rapidly absorbed [I. F. F. Benzie, “Lipid peroxidation: a review of causes, consequences, measurement and dietary influences,” International Journal of Food Sciences and Nutrition, vol. 47, no. 3, pp. 233–261, 1996.
View at: Google Scholar
J. L. Goldstein, Y. K. Ho, S. K. Basu, and M. S. Brown, “Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 1, pp. 333–337, 1979.
View at: Google Scholar
M. Ahotupa, J. P. Suomela, T. Vuorimaa, and T. Vasankari, “Lipoprotein-specific transport of circulating lipid peroxides,” Annals of Medicine, vol. 42, no. 7, pp. 521–529, 2010.
View at: Publisher Site | Google Scholar
J. Thiery and D. Seidel, “Fish oil feeding results in an enhancement of cholesterol-induced atherosclerosis in rabbits,” Atherosclerosis, vol. 63, no. 1, pp. 53–56, 1987.
View at: Google Scholar
B. Rauch, R. Schiele, S. Schneider et al., “OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction,” Circulation, vol. 122, no. 21, pp. 2152–2159, 2010.
View at: Publisher Site | Google Scholar
Consuming marine oil leads to increased plasma [
33] and urinary [L. A. Piche, H. H. Draper, and P. D. Cole, “Malondialdehyde excretion by subjects consuming cod liver oil vs a concentrate of n-3 fatty acids,” Lipids, vol. 23, no. 4, pp. 370–371, 1988.
View at: Google Scholar
L. A. Piche, H. H. Draper, and P. D. Cole, “Malondialdehyde excretion by subjects consuming cod liver oil vs a concentrate of n-3 fatty acids,” Lipids, vol. 23, no. 4, pp. 370–371, 1988.
View at: Google Scholar
L. A. Piche, H. H. Draper, and P. D. Cole, “Malondialdehyde excretion by subjects consuming cod liver oil vs a concentrate of n-3 fatty acids,” Lipids, vol. 23, no. 4, pp. 370–371, 1988.
View at: Google Scholar
M. J. Gonzalez, J. I. Gray, R. A. Schemmel, L. Dugan, and C. W. Welsch, “Lipid peroxidation products are elevated in fish oil diets even in the presence of added antioxidants,” Journal of Nutrition, vol. 122, no. 11, pp. 2190–2195, 1992.
View at: Google Scholar
A. K. Basu and L. J. Marnett, “Unequivocal demonstration that malondialdehyde is a mutagen,” Carcinogenesis, vol. 4, no. 3, pp. 331–333, 1983.
View at: Google Scholar
L. J. Marnett, “Lipid peroxidation—DNA damage by malondialdehyde,” Mutation Research, vol. 424, no. 1-2, pp. 83–95, 1999.
View at: Publisher Site | Google Scholar
M. Wang, K. Dhingra, W. N. Hittelman, J. G. Liehr, M. de Andrade, and D. Li, “Lipid peroxidation-induced putative malondialdehyde-DNA adducts in human breast tissues,” Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 9, pp. 705–710, 1996.
View at: Google Scholar
One human-randomized placebo-controlled trial has examined the effects of oxidized versus nonoxidized oil over 7 weeks [
57]. No difference was found in markers of in vivo lipid peroxidation (urinary 8-isoFGF2α, plasma HHE and HNE), markers of antioxidant activity, C-reactive protein, or liver function tests. This suggests that oxidized marine n-3 may not be associated with acute oxidative toxicity. However, this is not reassuring as the study was short and did not assess important pathological markers associated with atherosclerosis such as oxidized LDL or carotid artery intimal thickness. Further, there was no assessment of specific inflammatory markers such as prostaglandins and cytokines or of markers of DNA damage. Thus, the risks of atherosclerosis, DNA damage, malignancy, and inflammation especially at tissue level remain open. If low grade, chronic peroxide, aldehyde, or MDA exposure is important in disease it may require long periods of followup to identify an effect. Some pathological effects such as tissue level inflammation may be difficult to detect without invasive methods such as muscle, liver, or adipose tissue biopsy.In summary, given the paucity of specific evidence, it is currently impossible to know whether marine oils, some of the world’s most popular supplements, are safe after oxidation. The effects of oxidation on the biological effects of these oils may be complex, there could be both beneficial [
10,A. Mishra, A. Chaudhary, and S. Sethi, “Oxidized omega-3 fatty acids inhibit NF-κB activation via a PPARα-dependent pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 9, pp. 1621–1627, 2004.
View at: Publisher Site | Google Scholar
J. D. Brooks, E. S. Musiek, T. R. Koestner et al., “The fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation,” Journal of Neurochemistry, vol. 119, no. 3, pp. 604–616, 2011.
View at: Publisher Site | Google Scholar
7. Why Is the Omega-3 Supplementation Literature Conflicting?
The omega-3 supplementation literature is highly conflicting, especially in the area most heavily researched, the effect on cardiovascular disease. Oxidation may be a major cause of these conflicting results; however, it has never been reported in these trials.
Epidemiological studies link higher dietary [
58–M. L. Daviglus, J. Stamler, A. J. Orencia et al., “Fish consumption and the 30-year risk of fatal myocardial infarction,” The New England Journal of Medicine, vol. 336, no. 15, pp. 1046–1053, 1997.
View at: Publisher Site | Google Scholar
C. M. Albert, H. Campos, M. J. Stampfer et al., “Blood levels of long-chain n-3 fatty acids and the risk of sudden death,” The New England Journal of Medicine, vol. 346, no. 15, pp. 1113–1118, 2002.
View at: Publisher Site | Google Scholar
L. Djoussé, M. L. Biggs, R. N. Lemaitre et al., “Plasma omega-3 fatty acids and incident diabetes in older adults,” The American Journal of Clinical Nutrition, vol. 94, no. 2, pp. 527–533, 2011.
View at: Publisher Site | Google Scholar
D. S. Siscovick, T. E. Raghunathan, I. King et al., “Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest,” Journal of the American Medical Association, vol. 274, no. 17, pp. 1363–1367, 1995.
View at: Google Scholar
W. S. Harris, “n-3 fatty acids and lipoproteins: comparison of results from human and animal studies,” Lipids, vol. 31, no. 3, pp. 243–252, 1996.
View at: Publisher Site | Google Scholar
P. J. Nestel, “Fish oil attenuates the cholesterol induced rise in lipoprotein cholesterol,” American Journal of Clinical Nutrition, vol. 43, no. 5, pp. 752–757, 1986.
View at: Google Scholar
M. Kestin, P. Clifton, G. B. Belling, and P. J. Nestel, “n-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants,” American Journal of Clinical Nutrition, vol. 51, no. 6, pp. 1028–1034, 1990.
View at: Google Scholar
J. Dyerberg, J. H. Christensen, D. Eskesen, A. Astrup, and S. Stender, “Trans, and n-3 polyunsaturated fatty acids and vascular function—a yin yang situation?” Atherosclerosis Supplements, vol. 7, no. 2, pp. 33–35, 2006.
View at: Publisher Site | Google Scholar
G. K. Paschos, F. Magkos, D. B. Panagiotakos, V. Votteas, and A. Zampelas, “Dietary supplementation with flaxseed oil lowers blood pressure in dyslipidaemic patients,” European Journal of Clinical Nutrition, vol. 61, no. 10, pp. 1201–1206, 2007.
View at: Publisher Site | Google Scholar
D. Mozaffarian, A. Geelen, I. A. Brouwer, J. M. Geleijnse, P. L. Zock, and M. B. Katan, “Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials,” Circulation, vol. 112, no. 13, pp. 1945–1952, 2005.
View at: Publisher Site | Google Scholar
J. H. Christensen, P. Gustenhoff, E. Korup et al., “Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial,” British Medical Journal, vol. 312, no. 7032, pp. 677–678, 1996.
View at: Google Scholar
J. H. Christensen, M. S. Christensen, J. Dyerberg, and E. B. Schmidt, “Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids,” American Journal of Clinical Nutrition, vol. 70, no. 3, pp. 331–337, 1999.
View at: Google Scholar
T. A. Mori, L. J. Beilin, V. Burke, J. Morris, and J. Ritchie, “Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 2, pp. 279–286, 1997.
View at: Google Scholar
L. Axelrod, J. Camuso, E. Williams, K. Kleinman, E. Briones, and D. Schoenfeld, “Effects of a small quantity of ω-3 fatty acids on cardiovascular risk factors in NIDDM: a randomized, prospective, double-blind, controlled study,” Diabetes Care, vol. 17, no. 1, pp. 37–44, 1994.
View at: Google Scholar
F. Khan, K. Elherik, C. Bolton-Smith et al., “The effects of dietary fatty acid supplementation on endothelial function and vascular tone in healthy subjects,” Cardiovascular Research, vol. 59, no. 4, pp. 955–962, 2003.
View at: Publisher Site | Google Scholar
F. Thies, J. M. C. Garry, P. Yaqoob et al., “Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial,” The Lancet, vol. 361, no. 9356, pp. 477–485, 2003.
View at: Publisher Site | Google Scholar
R. De Caterina, R. Madonna, R. Zucchi, and M. T. La Rovere, “Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside,” American Heart Journal, vol. 146, no. 3, pp. 420–430, 2003.
View at: Publisher Site | Google Scholar
R. Marchioli, F. Barzi, E. Bomba et al., “Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione,” Circulation, vol. 105, no. 16, pp. 1897–1903, 2002.
View at: Publisher Site | Google Scholar
R. B. Singh, M. A. Niaz, J. P. Sharma, R. Kumar, V. Rastogi, and M. Moshiri, “Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival—4,” Cardiovascular Drugs and Therapy, vol. 11, no. 3, pp. 485–491, 1997.
View at: Publisher Site | Google Scholar
J. M. Geleijnse, E. J. Giltay, D. E. Grobbee, A. R. T. Donders, and F. J. Kok, “Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials,” Journal of Hypertension, vol. 20, no. 8, pp. 1493–1499, 2002.
View at: Publisher Site | Google Scholar
M. C. Morris, F. Sacks, and B. Rosner, “Does fish oil lower blood pressure? A meta-analysis of controlled trials,” Circulation, vol. 88, no. 2, pp. 523–533, 1993.
View at: Google Scholar
E. M. Balk, A. H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau, “Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review,” Atherosclerosis, vol. 189, no. 1, pp. 19–30, 2006.
View at: Publisher Site | Google Scholar
J. Bosch, H. C. Gerstein, G. R. Dagenais et al., “n-3 fatty acids and cardiovascular outcomes in patients with dysglycaemia,” The New England Journal of Medicine, vol. 367, no. 4, pp. 309–318, 2012.
View at: Publisher Site | Google Scholar
C. Wang, W. S. Harris, M. Chung et al., “n-3 fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review,” American Journal of Clinical Nutrition, vol. 84, no. 1, pp. 5–17, 2006.
View at: Google Scholar
E. C. Rizos, E. E. Ntzani, E. Bika, M. S. Kostapanos, and M. S. Elisaf, “Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 308, no. 10, pp. 1024–1033, 2012.
View at: Publisher Site | Google Scholar
B. Rauch, R. Schiele, S. Schneider et al., “OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction,” Circulation, vol. 122, no. 21, pp. 2152–2159, 2010.
View at: Publisher Site | Google Scholar
Y. Nakamura, H. Ueshima, T. Okamura et al., “Association between fish consumption and all-cause and cause-specific mortality in Japan: NIPPON DATA80, 1980–99,” American Journal of Medicine, vol. 118, no. 3, pp. 239–245, 2005.
View at: Publisher Site | Google Scholar
8. What Are the Implications for Interpretation of the Literature and Future Clinical Trials?
To assess the degree to which the importance of oxidation of marine oil is understood, we identified all human clinical trials published in 2012 using Pubmed. Of 107 reports, only one study investigating short-term harm reported the oxidative state of the trial oil (previously described) [
57]. This strongly suggests that the instability of marine oil is generally unrecognized or not considered important.It is currently impossible to determine how oxidation affects the efficacy or potential harms of marine oil. This makes interpretation of the clinical trial literature problematic. If the oxidative state of marine oils may affect efficacy or harm, then physicians should recommend, and consumers select, a supplement with the same oxidative state as the oils used in clinical trials that have shown benefit and safety. This is currently impossible because although over-the-counter-supplements are frequently oxidized [
23–C. M. Fantoni, A. P. Cuccio, and D. Barrera-Arellano, “Brazilian encapsulated fish oils: oxidative stability and fatty acid composition,” Journal of the American Oil Chemists' Society, vol. 73, no. 2, pp. 251–253, 1996.
View at: Google Scholar
That marine oils have beneficial effects on many indices such as plasma triglycerides, blood pressure, inflammation, and insulin sensitivity (in rodents) is not in question. The purpose of this commentary is to highlight the limited knowledge about the importance of oxidation to these effects. For example, some in vitro and animal studies have stored oil under conditions likely to prevent oxidation such as under nitrogen or at very low temperature [
94–A. González-Périz, R. Horrillo, N. Ferré et al., “Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins,” The FASEB Journal, vol. 23, no. 6, pp. 1946–1957, 2009.
View at: Publisher Site | Google Scholar
Ghafoorunissa, A. Ibrahim, L. Rajkumar, and V. Acharya, “Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats,” Journal of Nutrition, vol. 135, no. 11, pp. 2634–2638, 2005.
View at: Google Scholar
Future safety and efficacy trials, particularly in humans, should report the oxidative state of the marine oil. This could most easily be done by reporting the peroxide, anisidine, and TOTOX values. Even established benefits of marine oil need to be reinvestigated with provision of this information. In parallel, there should be a move to labelling marine oil supplements with these same oxidative indices and a production and storage chain that minimizes oxidation prior to purchase. Only then can we generalise efficacy and safety trial data to the available omega-3 supplements and provide informed recommendations to patients and consumers.
Conflict of Interests
The authors have no conflict of interests to declare.
Acknowledgments
The authors gratefully acknowledge the Sir Graeme and Lady Douglas Research Trust for generous support of Dr Albert’s research fellowship. The authors further thank Dr José Derraik for assistance in formatting the paper.